Fentanyl and its analogs, such as acetylfentanyl, have become a concern for potential abuse. Fentanyl compliance monitoring and urine drug testing are becoming increasingly necessary; however, a limited number of fentanyl immunoassays have been validated for clinical use. The purpose of this study was to validate the use of the DRI w fentanyl immunoassay, determine the potential cross-reactivity of acetylfentanyl and other pharmaceuticals, and investigate acetylfentanyl use in San Francisco. All urine toxicology samples from patients presenting to the emergency department were analyzed using the fentanyl immunoassay for 4 months. Positive samples were analyzed qualitatively using liquid chromatography -high resolution mass spectrometry (LC -HRMS) for fentanyl, fentanyl metabolites, fentanyl analogs and greater than 200 common drugs and metabolites. Subsequently, quantitative analysis was performed using LC-tandem mass spectrometry (LC -MS-MS). Acetylfentanyl, risperidone and 9-hydroxyrisperidone were found to cross-react with the fentanyl immunoassay. No acetylfentanyl was detected in our emergency department patient population. The fentanyl immunoassay demonstrated 100% diagnostic sensitivity in a subset of urines tested; however, the specificity was only 86% due to seven false-positive samples observed. Five of the seven samples were positive for risperidone and 9-hydroxyrisperidone. The DRI w fentanyl immunoassay can be used to screen for fentanyl or acetylfentanyl; however, confirmatory testing should be performed for all samples that screen positive.
Introduction
Fentanyl, a synthetic opioid, is a strong agonist at the m-opioid receptors, which produces euphoria, analgesia, sedation and respiratory depression (1) . It is mainly prescribed for chronic pain management and surgical anesthesia (1 -3) . In the mid-1970s, fentanyl appeared in the illicit drug market and remains a concern for potential abuse (4 -6) . Acetylfentanyl is an emerging designer fentanyl analog that has never been approved as a prescription drug, but rather is sold illegally. It is approximately five times the potency of heroin and overdose has been associated with more than 60 confirmed fatalities in Rhode Island, Pennsylvania, North Carolina and Louisiana in 2013 (7 -10) . No publications, to date, have reported acetylfentanyl use in the western USA.
Due to the potential for fentanyl abuse and diversion and the emergence of new fentanyl analogs, compliance monitoring and urine drug testing are becoming increasingly necessary. Fentanyl has a relatively short half-life, ranging from 3 to 12 h and is rapidly metabolized to norfentanyl, hydroxynorfentanyl, hydroxyfentanyl and despropionylfentanyl (3, 11) . Norfentanyl is the primary metabolite excreted in the urine and only 0.4-6% of fentanyl is eliminated unchanged (3, 11) . Due to the low urine fentanyl concentrations in patients treated for chronic pain, the detection of fentanyl can be a challenge for clinical and/or forensic laboratories (12) . A limited number of immunoassays have been developed for fentanyl screening and at least one is known to exhibit no cross-reactivity with norfentanyl (12) . In addition, the crossreactivity with fentanyl analogs is often unknown. Only one paper confirms that acetylfentanyl (as well as other fentanyl analogs) cross-reacts with a fentanyl ELISA (13) . Confirmatory fentanyl testing is highly recommended to determine whether it is a true positive screen or to confirm a suspected false negative (7, 8) . However, current confirmation testing is limited to fentanyl and some metabolites, which may contribute to a falsenegative confirmation test when the cause of the positive screen is a fentanyl analog or cross-reacting compound.
The purpose of this study was to validate the use of an automated DRI w fentanyl immunoassay for urine drug screening and determine the potential cross-reactivity of acetylfentanly and other pharmaceuticals. The fentanyl immunoassay was also used to investigate acetylfentanyl use in patients presenting to the emergency department at San Francisco General Hospital (SFGH).
Methods
All urine toxicology samples sent to the clinical laboratory (SFGH) from emergency department patients during a 4-month period (August -November 2013) were included in the study. The samples were analyzed using the DRI w fentanyl immunoassay (Thermo Scientific, Fremont, CA, USA) on an Advia1800 chemistry analyzer (Siemens, Malvern, PA) according to the manufacturer's recommendations using a 2-ng/mL cutoff.
All urines that screened positive were analyzed using LC -HRMS for fentanyl, fentanyl metabolites, fentanyl analogs and metabolites, and 200þ drugs and metabolites. The 200þ drugs and metabolites include common illicit drugs, pharmaceutical agents and metabolites (opioids, benzodiazepines, analgesics, sedatives, hypnotics, novel psychoactive substances, anti-depressants, antipsychotics, muscle relaxants and over the counter drugs). The urine samples were diluted 1 : 5 and separated using a Phenomenex Kinetex C 18 column (50 Â 3.00 mm, 2.6 mm) thermostatted at 308C with a 10-min gradient from 2 to 100% organic [mobile phase A (MPA)-5 mM NH 4 HCO 2 , 0.05% CH 2 O 2 and mobile phase B (MPB)-50 : 50 methanol : acetonitrile, 0.05% CH 2 O 2 ]. Mass detection was carried out with an ABSciex TripleTOF w 5600 operating in positive-ion HRMS full scan mode with information dependent acquisition of HRMS product ion spectra. All urines that screened positive for fentanyl (N ¼ 36) and fentanyl-negative urine samples (N ¼ 43), collected during the same time frame, were further tested by a quantitative LC -MS-MS method for fentanyl, norfentanyl, acetylfentanyl, risperidone and 9-hydroxyrisperidone. The urine samples were diluted 1 : 5 with internal standard and separated using a Phenomenex Kinetex Phenyl-Hexyl column (50 Â 4.6 mm, 2.6 mm) thermostatted at 308C with a 7-min gradient from 20 to 95% organic (MPA-10 mM NH 4 HCO 2 in H 2 O and MPB-0.1% CH 2 O 2 in methanol). Mass detection was carried out with an ABSciex QTRAP w 3200 LC -MS-MS operating in ESI-positive-ion multiple reaction monitoring mode. The limit of detection for all analytes tested was 0.1 ng/mL.
Cross-reactivity of norfentanyl, acetylfentanyl, risperidone and 9-hydroxyrisperidone with the fentanyl immunoassay was analyzed by spiking standards of each compound (obtained from Cerilliant, Round Rock, TX, USA) in drug-free urine at increasing concentrations (N ¼ 3 at each concentration) and testing them in the same manner as the patient samples.
Results
During a 4-month period, 1,269 urine samples were sent to the clinical laboratory from the emergency department for urine drug testing. Thirty-six samples (3%) screened positive using the fentanyl DRI w immunoassay. Of the 36 positive samples, 29 confirmed positive for fentanyl using the LC -HRMS method and 7 were determined to be false positives. Risperidone and 9-hydroxyrisperidone were detected in five of seven falsepositive urine samples. Both compounds were also identified in three additional urine samples that also contained fentanyl. There were two false-positive samples that did not screen positive by LC-HRMS for fentanyl, fentanyl metabolites, fentanyl analogs and known metabolites, risperidone, 9-hydroxyrisperidone or other risperidone metabolites. None of the drugs or metabolites identified in these two samples were found to cross-react with the fentanyl immunoassay upon testing up to 100,000 ng/ mL (lorazepam, diphenhydramine, benzoylecgonine, cocaine, amphetamine, methamphetamine, chlorpheniramine, citalopram and N-desmethylcitalopram). Acetylfentanyl, acetyl norfentanyl and other fentanyl analogs were not detected in any of the 36 samples.
All urines that screened positive by the fentanyl immunoassay (N ¼ 36) and urine samples that were fentanyl negative (N ¼ 43) were tested using a quantitative LC-MS-MS method for fentanyl, norfentanyl, acetylfentanyl, risperidone and 9-hydroxyrisperidone. The quantitative results can be seen in Table I for the samples that screened positive for fentanyl. The LC -MS-MS quantitative results correlated with the LC -HRMS qualitative results for the samples that screened positive (seven false positives). All samples that screened negative confirmed negative for fentanyl and norfentanyl resulting in zero false-negative results. Therefore, the diagnostic sensitivity and specificity of the fentanyl DRI w immunoassay in this study was 100 and 86%, respectively.
Fentanyl DRI w immunoassay cross-reactivity was further analyzed through spiking studies. Acetylfentanyl, risperidone and 9-hydroxyrisperidone showed cross-reactivity starting at 2.5, 3,500 and 12,500 ng/mL, respectively. The resulting percent cross-reactivity was 80% for acetylfentanyl, 0.05% for risperidone and 0.01% for 9-hydroxyrisperidone. The dose-response curves for fentanyl and these three compounds are shown in Figure 1 . Norfentanyl did not cross-react with the fentanyl immunoassay up to 1,000 ng/mL, which was the highest concentration tested.
Discussion
This study is the first to validate the use of the DRI w fentanyl immunoassay and to assess potential cross-reactivity with acetylfentanyl and other pharmaceuticals. Acetylfentanyl was found to cross-react with the fentanyl immunoassay. All urine drug screens sent to the clinical laboratory from the emergency department for a 4-month period (N ¼ 1,269) either screened negative using the fentanyl immunoassay or screened positive and confirmed negative for acetylfentanyl and nor acetylfentanyl. These results suggest that acetylfentanyl is not being used in our patient population. Generalizability of these findings is limited by the observational study design with convenience sampling of patients from a single emergency department in one geographical area. Only one study, to date, has confirmed that acetylfentanyl cross-reacts with an ELISA assay specifically designed to detect fentanyl (13) . Our results confirm that the DRI w fentanyl immunoassay can be used to screen for acetylfentanyl; however, confirmatory testing should be performed for all samples that screen positive to determine if the sample contains fentanyl, acetylfentanyl or is a false positive. There are still no studies to date that report the use of acetylfentanyl outside of the eastern USA.
Risperidone and 9-hydroxyrisperidone were also found to cross-react with the DRI w fentanyl immunoassay, whereas norfentanyl does not. Risperidone is an antipsychotic agent commonly used for treating autism spectrum disorder, bipolar disorder and schizophrenia (14, 15) . The metabolism of risperidone (half-life 3 -20 h) is through the route of dealkylation, hydroxylation or benzisoxazole ring scissions with 9-hydroxyrisperidone being the primary active metabolite (3). Fentanyl, acetylfentany, risperidone and 9-hydroxyrisperidone all share a similar chemical moiety that is not present in norfentanyl (Figure 1, insets) . This intramolecular alkylated piperadine (3-methyl-5-piperidino-2-pentene) is likely recognized in-part by the antibody for the immunoassay.
The highest concentrations of risperidone and 9-hydroxyrisperidone measured in the patient samples were 2,701 and 3,043 ng/mL, respectively (Table I) . However, the crossreactivity in the fentanyl immunoassay was only observed at concentrations !3,500 ng/mL for risperidone ( Figure 1C ) and !12,500 ng/mL for 9-hydroxyrisperidone in the spiking studies ( Figure 1D) . The results suggest that other risperidone metabolites may also be involve in the cross-reactivity. Using LC-HRMS for screening, we were able to identify peaks that correspond to the molecular formula of other known risperidone metabolites in these samples; however, we were unable to confirm these findings due to the unavailability of analytical standards for these metabolites. The urine concentrations observed in these samples are likely obtained from therapeutic dosing since the only toxic risperidone urine concentration reported in the literature is 14,400 ng/mL (16) . Expected concentrations of risperidone and 9-hydroxyrisperidone in urine following routine administration are unreported.
The evaluation of the DRI w fentanyl immunoassay demonstrated excellent diagnostic sensitivity (100%), detecting all 29 LC-MS-MS fentanyl positive urine samples out of a total of 79 samples tested. However, the specificity of this assay was only 86% due to the seven false-positive samples observed. Five of the seven samples were positive for risperidone and 9-hydroxyrisperidone. There were two samples that screened positive using the fentanyl immunoassay, but confirmed negative for fentanyl, fentanyl metabolites, fentanyl analogs, risperidone and 9-hydroxyrisperidone. The immunoassay screening value was very close to the 2-ng/mL cutoff in both samples. It is unknown what is causing the cross-reactivity in these samples. Screening for 200þ drugs and metabolites by LC-HRMS did not yield any promising candidates. The cross-reactivity from other compounds needs to be further investigated. , risperidone (C), and 9-hydroxyrisperidone. Insets: Chemical structures of the corresponding compounds. The intramolecular alkylated piperidine (3-methyl-5-piperidino-2-pentene) common to fentanyl, acetylfentanyl, risperidone and 9-hydroxyrisperidone is highlighted for each compound.
